Skip to search formSkip to main contentSkip to account menu

ponalrestat

Known as: 3-(4-Bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-1-phthalazineacetic Acid, 3-(4-bromo-2-fluorobenzyl)-3,4-dihydro-4-oxo-3H-phthalazin-1-ylacetic acid 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
1 The aim of the study was to examine the effects in rats of two different doses of the aldose reductase inhibitor, ponalrestat… 
Highly Cited
1991
Highly Cited
1991
Hyperglycemia causes enhanced glucose metabolism by the polyol pathway in tissues not requiring insulin for glucose uptake. It… 
Highly Cited
1990
Highly Cited
1990
There is controversy over the efficacy of aldose reductase inhibitors in preventing the development of peripheral nerve lesions…